ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
Publication Type:
Journal Article
Authors:
Andreone, P.;
Colombo, M.G.;
Enejosa, J.V.;
Koksal, I.;
Ferenci, P.;
Maieron, A.;
Mullhaupt, B.;
Horsmans, Y.;
Weiland, O.;
Hendrick W Reesink;
Rodrigues, L., Jr.;
Hu, Y.B.;
Podsadecki, T.;
Bernstein, B.Source:
Gastroenterology, Volume 147, Issue 2, p.359-365 (2014)
Keywords:
Adult,
adverse effects,
Aged,
analogs & derivatives,
Anilides,
Antiviral Agents,
Austria,
Belgium,
Biological Markers,
blood,
Carbamates,
Chicago,
clinical trial,
diagnosis,
drug effects,
drug therapy,
Drug Therapy,Combination,
Europe,
Fatigue,
Female,
genetics,
Genotype,
growth & development,
HCV,
Headache,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Humans,
Illinois,
Infection,
Internal Medicine,
Italy,
Macrocyclic Compounds,
Male,
Medicine,
methods,
Middle Aged,
Multicenter Studies,
Netherlands,
NS5A inhibitor,
Patients,
peginterferon,
protease inhibitor,
Puerto Rico,
Research,
Research Support,
Ribavirin,
ritonavir,
Rna,
Rna,Viral,
Sulfonamides,
sustained virologic response,
SVR,
Sweden,
Switzerland,
Telaprevir,
therapeutic use,
Time Factors,
treatment,
Treatment Outcome,
Turkey,
United States,
Universities,
Uracil,
Viral Load
